A research storyline aimed at solid tumors is again testing a long-held immunotherapy premise: whether T cells must be antigen-specific to eliminate cancer. In discussion of an intratumoral T-cell activation paper, the idea is that activating existing T cells within the tumor microenvironment may drive tumor regression even when T-cell specificity is mismatched. The implication for translational oncology is direct—development programs centered on engineered, specificity-driven cellular therapies may face additional competition from approaches that prioritize broad intratumoral stimulation and microenvironment conditioning. Further validation will likely be needed across tumor types and with prospective experimental designs.